Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Mochida Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co., Ltd.

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

持田製薬株式会社 develops and sells pharmaceuticals and healthcare products. The company's offerings include skin care products and patient information websites, as well as services aimed at supporting various medical conditions.

Metric
Company Name	Mochida Pharmaceutical Co., Ltd.	Santen Pharmaceutical Co., Ltd.	Idorsia Ltd
Symbol	4.53K	4.54K	IDIA
MSH ID	JP:CO:MOCHIDA	COM:SANTEN	COM:IDORSIA
Market	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - General
Country	JP	JP	CH
Stage			Post-IPO Debt
Employee Count	1.52K	3.74K	636
Website	mochida.co.jp	santen.com	idorsia.com
LinkedIn
Founders

Metric
Market Cap	786.46M	4.34B	311.77M
Enterprise Value
Monthly Web Traffic	307.34K		19.83K
Web Traffic Growth	-0.23		1.09
Valuation
Raised Capital			83.54M

Metric
Revenue	686.17M	2.01B	173.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	347.27M	1.09B	143.86M
EBITDA	57.43M	467.39M	-597.34M
Operating Income	38.70M	346.16M	-619.04M
Net Income	30.33M	177.68M	-339.61M
EPS	0.85	0.48	-1.90
Diluted EPS	0.85	0.48	-1.90
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.51	0.61	0.95
Operating Profit Margin	0.06	0.16	-0.52
EBITDA Margin	0.08	0.23	-3.44
Net Profit Margin	0.04	0.09	0.31
Return on Equity	0.04	0.09	0.44
Return on Assets	0.03	0.06	0.06
Return on Capital Employed	0.04	0.14	-0.29

JP:CO:MOCHIDA

持田製薬株式会社

Last Close

3,315.00

25/11 06:45

Market Cap

117.88B

Beta: -

Volume Today

19.20K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	20.92	19.65	-0.73
P/B Ratio	0.91	1.69	-0.33
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.22	2.20	4.46
EV Multiple	36.51	11.60	14.37

Metric
Days Sales Outstanding	114.66	115.31	52.13
Days Payables Outstanding	71.56	137.47	751.10
Days Inventory Outstanding	222.75	146.05	2.47K
Operating Cycle	350.74	246.43	2.52K
Cash Conversion Cycle	267.42	165.05	1.77K
Asset Turnover	0.66	0.71	0.28

Metric
Operating Cash Flow	-49.89M	484.52M	-717.35M
Free Cash Flow	-65.20M	413.25M	-728.06M
Cash Flow to Debt		2.52	-0.35
Operating Cash Flow/Sales	0.01	0.27	-3.00
Free Cash Flow Yield		0.06	-2.60

Metric
Cash & Equivalents	222.02M	630.80M	165.35M
Accounts Receivable	-46.90M	122.61M	-14.68M
Inventory	201.93M	288.02M	67.42M
Goodwill
Debt to Capitalization	0.00	0.10	11.32
Debt to Assets			1.85
Current Ratio	4.62	2.66	1.21
Quick Ratio	3.31	2.08	1.00

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.18
R&D to Revenue	0.09	1.94
SG&A to Revenue	0.33	4.00